US Pharma Marketing“Deprescribing requires gradual tapering, psychological support, careful risk stratification, and accessible alternatives — none of which Kennedy’s initiative provides at scale.” chronic disease FDA HHS Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home First Opinion RFK Jr.’s antidepressant deprescribing push gets one thing right — and others…
I recently helped a woman in her early 60s taper off fluoxetine (often known by the brand name Prozac), which she had taken for over 35 years, followed by bupropion (aka Wellbutrin), which she had taken for over a decade.
But Kennedy’s initiative conflates that genuine clinical need with claims unsupported by evidence — and some that are actively dangerous.
Source: STAT News Pharma